

(¥ million)

	2015	2016	2017	2018	2019	2020	2021 (estimated)
Net Sales	84,209	98,781	101,448	114,716	116,637	121,885	135,000
Operating profit	8,549	15,280	17,079	20,644	21,668	26,134	28,000
Ordinary Profit	8,952	16,244	17,451	21,540	22,442	26,760	28,500
Profit attributable to owners of parent	6,340	11,749	12,953	16,302	16,866	20,702	21,000

May 14, 2021

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2019	Sales 2020	Sales 2021 (estimated)	
						Apr-Sep	Annual
Vidaza	azacitidine	myelodysplastic syndrome	Mar-11	15,652	15,350	8,300	17,200
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-10	7,153	6,906	3,000	6,100
Uptravi	selexipag	pulmonary arterial hypertension	Nov-16	6,182	6,804	3,900	8,600
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-14	13,328	6,743	1,800	3,200
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-09	5,405	5,474	2,600	4,800
Gazyva	obinutuzumab	CD20-positive follicular lymphoma	Aug-18	4,527	5,312	2,900	6,100
Cialis	tadalafil	erectile dysfunction	Jul-09	4,472	2,677	1,300	2,500
Erizas	dexamethasone cipeclilate	allergic rhinitis	Dec-09	2,387	2,444	800	2,500
Viltepso	viltolarsen	Duchenne muscular dystrophy	Japan May-20 US Aug-20	-	2,387	3,500	8,800
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-19	1,071	1,970	1,000	2,100
Profit in co-promotion				5,963	8,442	4,400	9,000
Revenues from the licensing of industrial				15,860	24,338	20,200	32,000
Pharmaceuticals				101,643	106,478	61,800	119,300
Functional Food				14,994	15,406	7,700	15,700
Net Sales				116,637	121,885	69,500	135,000